Mereo BioPharma Group plc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
United Kingdom
Country
United Kingdom
Business Address
ONE CAVENDISH PLACE, LONDON, , W1G 0QF
Mailing Address
ONE CAVENDISH PLACE, LONDON, , W1G 0QF
Phone
4403330237300
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2023
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Developing new medicines for rare diseases and cancer, with a diverse pipeline of drug candidates.
- Setrusumab, a key drug candidate for Osteogenesis Imperfecta (OI), is in advanced Phase 2/3 clinical trials.
Material Events
8-K
Financial Distress
February 17, 2026
High Impact
- Mereo BioPharma Group plc received a formal Nasdaq delisting warning on February 17, 2026.
- The warning is due to its American Depositary Shares (ADSs) trading below the $1.00 minimum bid price for 30 consecutive business days.
8-K
Other
January 12, 2026
High Impact
- Mereo BioPharma has a cash runway extending until mid-2027, providing a solid timeframe for operations.
- The company had approximately $41 million in cash and cash equivalents as of December 31, 2025.
8-K
Other
December 29, 2025
High Impact
- Mereo BioPharma announced results from two Phase 3 clinical trials (Orbit and Cosmic) for setrusumab (UX143) in osteogenesis imperfecta (OI).
- Setrusumab significantly improved bone mineral density (BMD) in patients.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.